Tarsus Pharmaceuticals Net Income
| TARS Stock | USD 65.71 1.53 2.38% |
As of the 30th of January, Tarsus Pharmaceuticals has the Semi Deviation of 2.06, coefficient of variation of 13627.63, and Risk Adjusted Performance of 0.0121. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tarsus Pharmaceuticals, as well as the relationship between them. Please validate Tarsus Pharmaceuticals information ratio and downside variance to decide if Tarsus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 65.71 per share. Given that Tarsus Pharmaceuticals has jensen alpha of (0.02), we advise you to double-check Tarsus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.
Tarsus Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.5428 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -104 M | -98.8 M | |
| Net Loss | -55.9 M | -53.1 M | |
| Net Loss | -104 M | -98.8 M | |
| Net Loss | (3.53) | (3.71) | |
| Net Income Per E B T | 0.90 | 0.80 |
Tarsus | Net Income | Build AI portfolio with Tarsus Stock |
The evolution of Net Income for Tarsus Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Tarsus Pharmaceuticals compares to historical norms and industry peers.
Latest Tarsus Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Tarsus Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Tarsus Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Tarsus Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Tarsus Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tarsus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (115.55 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Tarsus Net Income Regression Statistics
| Arithmetic Mean | (33,736,134) | |
| Coefficient Of Variation | (144.17) | |
| Mean Deviation | 40,900,541 | |
| Median | (1,319,000) | |
| Standard Deviation | 48,638,424 | |
| Sample Variance | 2365.7T | |
| Range | 134.6M | |
| R-Value | (0.81) | |
| Mean Square Error | 858.7T | |
| R-Squared | 0.66 | |
| Significance | 0.000075 | |
| Slope | (7,823,092) | |
| Total Sum of Squares | 37851.1T |
Tarsus Net Income History
Other Fundumenentals of Tarsus Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Tarsus Pharmaceuticals Net Income component correlations
Tarsus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tarsus Pharmaceuticals is extremely important. It helps to project a fair market value of Tarsus Stock properly, considering its historical fundamentals such as Net Income. Since Tarsus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tarsus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tarsus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Tarsus introduce new products? Factors like these will boost the valuation of Tarsus Pharmaceuticals. If investors know Tarsus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Tarsus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.99) | Revenue Per Share | Quarterly Revenue Growth 1.467 | Return On Assets | Return On Equity |
Understanding Tarsus Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Tarsus's accounting equity. The concept of intrinsic value—what Tarsus Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Tarsus Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tarsus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tarsus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tarsus Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Tarsus Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tarsus Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tarsus Pharmaceuticals.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Tarsus Pharmaceuticals on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Tarsus Pharmaceuticals or generate 0.0% return on investment in Tarsus Pharmaceuticals over 90 days. Tarsus Pharmaceuticals is related to or competes with Disc Medicine, Legend Biotech, Travere Therapeutics, Zai Lab, CG Oncology, Celcuity LLC, and Scholar Rock. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializati... More
Tarsus Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tarsus Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tarsus Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.13 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 12.48 | |||
| Value At Risk | (3.76) | |||
| Potential Upside | 3.78 |
Tarsus Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tarsus Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tarsus Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Tarsus Pharmaceuticals historical prices to predict the future Tarsus Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0121 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.15) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0124 |
Tarsus Pharmaceuticals January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0121 | |||
| Market Risk Adjusted Performance | 0.0224 | |||
| Mean Deviation | 1.56 | |||
| Semi Deviation | 2.06 | |||
| Downside Deviation | 2.13 | |||
| Coefficient Of Variation | 13627.63 | |||
| Standard Deviation | 2.23 | |||
| Variance | 4.97 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.15) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0124 | |||
| Maximum Drawdown | 12.48 | |||
| Value At Risk | (3.76) | |||
| Potential Upside | 3.78 | |||
| Downside Variance | 4.53 | |||
| Semi Variance | 4.26 | |||
| Expected Short fall | (1.67) | |||
| Skewness | 0.2109 | |||
| Kurtosis | 1.04 |
Tarsus Pharmaceuticals Backtested Returns
Tarsus Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0327, which indicates the firm had a -0.0327 % return per unit of risk over the last 3 months. Tarsus Pharmaceuticals exposes thirty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Tarsus Pharmaceuticals' Risk Adjusted Performance of 0.0121, semi deviation of 2.06, and Coefficient Of Variation of 13627.63 to confirm the risk estimate we provide. The entity has a beta of 0.51, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tarsus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tarsus Pharmaceuticals is expected to be smaller as well. At this point, Tarsus Pharmaceuticals has a negative expected return of -0.0738%. Please make sure to validate Tarsus Pharmaceuticals' downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Tarsus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.67 |
Very good reverse predictability
Tarsus Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between Tarsus Pharmaceuticals time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tarsus Pharmaceuticals price movement. The serial correlation of -0.67 indicates that around 67.0% of current Tarsus Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.67 | |
| Spearman Rank Test | -0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 32.22 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Tarsus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Tarsus Pharmaceuticals reported net income of (115.55 Million). This is 133.86% lower than that of the Pharmaceuticals sector and 264.97% lower than that of the Health Care industry. The net income for all United States stocks is 120.24% higher than that of the company.
Tarsus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tarsus Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics of similar companies.Tarsus Pharmaceuticals is currently under evaluation in net income category among its peers.
Tarsus Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tarsus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tarsus Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Tarsus Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Tarsus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tarsus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tarsus Pharmaceuticals' value.| Shares | Lord, Abbett & Co Llc | 2025-06-30 | 995.4 K | State Street Corp | 2025-06-30 | 980.9 K | Macquarie Group Ltd | 2025-06-30 | 948.9 K | Geode Capital Management, Llc | 2025-06-30 | 934.4 K | Amvescap Plc. | 2025-06-30 | 928.5 K | Driehaus Capital Management Llc | 2025-06-30 | 876.5 K | D. E. Shaw & Co Lp | 2025-06-30 | 723.2 K | Adage Capital Partners Gp Llc | 2025-06-30 | 543 K | Artisan Partners Limited Partnership | 2025-06-30 | 539.3 K | Blackrock Inc | 2025-06-30 | 3.8 M | Rtw Investments, Llc | 2025-06-30 | 3.1 M |
Tarsus Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 2.4 B | ||||
| Shares Outstanding | 42.45 M | ||||
| Shares Owned By Insiders | 3.03 % | ||||
| Shares Owned By Institutions | 96.97 % | ||||
| Number Of Shares Shorted | 5.37 M | ||||
| Price To Book | 8.13 X | ||||
| Price To Sales | 7.62 X | ||||
| Revenue | 182.95 M | ||||
| Gross Profit | 278.26 M | ||||
| EBITDA | (106.48 M) | ||||
| Net Income | (115.55 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 72.45 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 7.89 X | ||||
| Cash Flow From Operations | (83.03 M) | ||||
| Short Ratio | 7.88 X | ||||
| Earnings Per Share | (1.99) X | ||||
| Price To Earnings To Growth | 0.28 X | ||||
| Target Price | 87.89 | ||||
| Number Of Employees | 323 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 2.79 B | ||||
| Total Asset | 376.99 M | ||||
| Retained Earnings | (360.21 M) | ||||
| Working Capital | 276.09 M | ||||
| Net Asset | 376.99 M |
About Tarsus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tarsus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.